Head-To-Head Survey: Celldex Therapeutics (CLDX) versus IPSEN S A/S (IPSEY)

Celldex Therapeutics (NASDAQ: CLDX) and IPSEN S A/S (OTCMKTS:IPSEY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.


This table compares Celldex Therapeutics and IPSEN S A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celldex Therapeutics -1,157.96% -47.36% -33.16%

Institutional and Insider Ownership

51.7% of Celldex Therapeutics shares are held by institutional investors. 2.9% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


IPSEN S A/S pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. Celldex Therapeutics does not pay a dividend. IPSEN S A/S pays out 23.7% of its earnings in the form of a dividend.

Volatility and Risk

Celldex Therapeutics has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500. Comparatively, IPSEN S A/S has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Celldex Therapeutics and IPSEN S A/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics 0 3 3 0 2.50
IPSEN S A/S 0 0 1 0 3.00

Celldex Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 800.00%. Given Celldex Therapeutics’ higher possible upside, equities analysts clearly believe Celldex Therapeutics is more favorable than IPSEN S A/S.

Earnings & Valuation

This table compares Celldex Therapeutics and IPSEN S A/S’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celldex Therapeutics $12.74 million 5.63 -$93.03 million ($0.80) -0.63
IPSEN S A/S $2.27 billion 5.71 $307.78 million $0.93 41.65

IPSEN S A/S has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than IPSEN S A/S, indicating that it is currently the more affordable of the two stocks.


IPSEN S A/S beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.


Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply